Scholar Rock’s share price dropped over 5% after the company reported a net loss of $110 million in the second quarter, far exceeding expectations. The company’s expenses surged, with general and administrative costs almost tripling. Despite the disappointing financials, Scholar Rock has a strong cash position of $295 million. The company remains optimistic about its future, with the FDA accepting its biologics license application for a drug targeting spinal muscular atrophy. However, it wasn’t among the 10 best stocks recommended by The Motley Fool Stock Advisor team.

Read more at Yahoo Finance: Why Scholar Rock Stock Wilted on Wednesday